Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (RESPIRE 1)

January 3, 2018 updated by: Bayer

Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.

The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Number of participants with Adverse events will be covered in Adverse Events section.

The statistical analysis tests for the efficacy variables will be performed hierarchically. The comparisons ciprofloxacin DPI vs. pooled placebo (according to statistical analysis plan defined for FDA registration) will be performed in parallel for the regimen 28 days on/off and 14 days on/off.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
416

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Vicente López, Argentina, 1638
    • Ciudad Auton. De Buenos Aires
      • Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina, C1425DES
    • Mendoza
      • Godoy Cruz, Mendoza, Argentina, 5501
  • Australia
      • Box Hill, Australia, 3128
      • Cairns, Australia, 4870
      • Frankston, Australia, 3199
      • Kogarah, Australia, 2217
      • Toorak Gardens, Australia, 5065
    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
    • South Australia
      • Adelaide, South Australia, Australia, 5000
      • Adelaide, South Australia, Australia, 5041
      • Woodville, South Australia, Australia, 5011
    • Victoria
      • Parkville, Victoria, Australia, 3050
      • Prahran, Victoria, Australia, 3181
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
  • Denmark
      • Aarhus C, Denmark, 8000
      • Hellerup, Denmark, 2900
      • Naestved, Denmark, 4700
      • Roskilde, Denmark, 4000
  • France
      • Clermont Ferrand, France, 63000
      • Montpellier, France, 34059
      • Nimes, France, 30900
      • Toulon, France, 83000
  • Germany
      • Berlin, Germany, 10969
      • Berlin, Germany, 12203
      • Berlin, Germany, 10717
      • Hamburg, Germany, 22767
    • Baden-Württemberg
      • Heidelberg, Baden-Württemberg, Germany, 69126
    • Brandenburg
      • Cottbus, Brandenburg, Germany, 03050
    • Hessen
      • Frankfurt, Hessen, Germany, 60389
      • Neu-Isenburg, Hessen, Germany, 63263
    • Niedersachsen
      • Hannover, Niedersachsen, Germany, 30625
      • Hannover, Niedersachsen, Germany, 30173
    • Rheinland-Pfalz
      • Koblenz, Rheinland-Pfalz, Germany, 56068
    • Schleswig-Holstein
      • Geesthacht, Schleswig-Holstein, Germany, 21502
    • Thüringen
      • Jena, Thüringen, Germany, 07740
  • Israel
      • Afula, Israel, 1834111
      • Ashkelon, Israel, 7827804
      • Beer Sheva, Israel, 8410101
      • Haifa, Israel, 3109601
      • Haifa, Israel, 3436212
      • Jerusalem, Israel, 9112001
      • Petah Tikva, Israel, 4941492
      • Ramat Gan, Israel, 5262000
      • Rehovot, Israel, 7610001
      • Tel Aviv, Israel, 6423906
  • Italy
    • Campania
      • Benevento, Campania, Italy, 82037
    • Friuli-Venezia Giulia
      • Trieste, Friuli-Venezia Giulia, Italy, 34149
    • Lazio
      • Roma, Lazio, Italy, 00168
    • Lombardia
      • Pavia, Lombardia, Italy, 27040
      • Varese, Lombardia, Italy, 21049
    • Puglia
      • Bari, Puglia, Italy, 70020
    • Sardegna
      • Cagliari, Sardegna, Italy, 09126
    • Sicilia
      • Catania, Sicilia, Italy, 95123
    • Toscana
      • Pisa, Toscana, Italy, 56124
    • Veneto
      • Verona, Veneto, Italy, 37126
  • Japan
      • Fukuoka, Japan, 811-1394
    • Ehime
      • Toon, Ehime, Japan, 791-0281
    • Ibaraki
      • Nakagun, Ibaraki, Japan, 319-1113
    • Kumamoto
      • Koshi, Kumamoto, Japan, 861-1196
    • Mie
      • Matsusaka, Mie, Japan, 515-8544
      • Tsu, Mie, Japan, 514-1101
    • Osaka
      • Sakai, Osaka, Japan, 591-8555
    • Shizuoka
      • Hamamatsu, Shizuoka, Japan, 434-8511
    • Tokyo
      • Kiyose, Tokyo, Japan, 204-8585
      • Mitaka, Tokyo, Japan, 181-8611
  • Latvia
      • Daugavpils, Latvia, LV-5403
      • Daugavpils, Latvia, LV-5410
      • Jurmala, Latvia, LV-2010
      • Kraslava, Latvia, 5601
      • Riga, Latvia, LV-1002
      • Riga, Latvia, LV-1038
      • Riga, Latvia, LV-1001
      • Riga, Latvia, LV-1011
      • Talsu, Latvia, 3201
  • New Zealand
      • Auckland, New Zealand, 1051
      • Auckland, New Zealand, 1640
      • Christchurch, New Zealand, 8011
      • Dunedin, New Zealand
      • Hamilton, New Zealand, 3240
      • Tauranga, New Zealand, 3110
      • Wellington, New Zealand, 6021
  • Slovakia
      • Bratislava, Slovakia, 821 06
      • Presov, Slovakia, 080 01
  • Spain
      • Barcelona, Spain, 08036
      • Barcelona, Spain, 08041
      • Cáceres, Spain, 10003
      • Madrid, Spain, 28006
      • Madrid, Spain, 28040
      • Madrid, Spain, 28034
      • Pontevedra, Spain, 36071
      • Valencia, Spain, 46017
      • Valencia, Spain, 46026
    • A Coruña
      • Santiago de Compostela, A Coruña, Spain, 15706
    • Alicante
      • Elda, Alicante, Spain, 03600
    • Asturias
      • Oviedo, Asturias, Spain, 33006
    • Barcelona
      • Badalona, Barcelona, Spain, 08916
      • L'Hospitalet, Barcelona, Spain, 08907
      • Sant Boi de Llobregat, Barcelona, Spain, 08830
      • Terrassa, Barcelona, Spain, 08221
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spain, 28223
  • United Kingdom
      • London, United Kingdom, SW3 6NP
      • Londonderry, United Kingdom, BT47 6SB
      • Manchester, United Kingdom, M23 9LT
    • Cambridgeshire
      • Cambridge, Cambridgeshire, United Kingdom, CB23 3RE
    • Devon
      • Exeter, Devon, United Kingdom, EX2 5DW
      • Plymouth, Devon, United Kingdom, PL6 8DH
      • Torbay, Devon, United Kingdom, TQ2 7AA
    • Dundee City
      • Dundee, Dundee City, United Kingdom, DD1 9SY
    • North Ireland
      • Belfast, North Ireland, United Kingdom, BT12 7AB
    • Shropshire
      • Shrewsbury, Shropshire, United Kingdom, SY3 8XQ
    • Tyne And Wear
      • Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE7 7DN
  • United States
    • Alabama
      • Jasper, Alabama, United States, 35501
    • Arizona
      • Flagstaff, Arizona, United States, 86001
      • Phoenix, Arizona, United States, 85006-2611
      • Scottsdale, Arizona, United States, 85258
    • Arkansas
      • Fort Smith, Arkansas, United States, 72901
    • California
      • Los Angeles, California, United States, 90048
      • Torrance, California, United States
      • Ventura, California, United States, 93003
    • Connecticut
      • Farmington, Connecticut, United States, 06030
      • Waterbury, Connecticut, United States, 06708-2513
    • District of Columbia
      • Washington, District of Columbia, United States, 20007-2197
    • Florida
      • Celebration, Florida, United States, 34747
      • Miami, Florida, United States, 33136
      • Orlando, Florida, United States, 32803
      • Weston, Florida, United States, 33331
      • Winter Park, Florida, United States, 32789
    • Georgia
      • Lawrenceville, Georgia, United States, 30046
      • Marietta, Georgia, United States, 30060
    • Illinois
      • Chicago, Illinois, United States, 60637
    • Indiana
      • Michigan City, Indiana, United States, 46360
    • Kentucky
      • Hazard, Kentucky, United States, 41701
    • Missouri
      • Chesterfield, Missouri, United States, 63017
    • New Jersey
      • Summit, New Jersey, United States, 07901
    • New York
      • New Hyde Park, New York, United States, 11042
      • New York, New York, United States, 10016
    • Oregon
      • Portland, Oregon, United States, 97239-3011
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
      • Philadelphia, Pennsylvania, United States, 19140
    • South Carolina
      • Charleston, South Carolina, United States, 29425
    • Texas
      • Fort Worth, Texas, United States, 76104
      • Houston, Texas, United States, 77030
      • Houston, Texas, United States, 77043
      • Kingwood, Texas, United States, 77339
      • McKinney, Texas, United States, 75069
      • Tyler, Texas, United States, 75708-3154
    • Virginia
      • Abingdon, Virginia, United States, 24210
      • Richmond, Virginia, United States, 23225
    • Washington
      • Spokane, Washington, United States, 99202-1334
      • Tacoma, Washington, United States, 98405

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with a proven and documented diagnosis of non Cystic Fibrosis (CF) idiopathic or post infectious bronchiectasis
  • Stable pulmonary status and stable regimen of standard treatment at least for the past 4 weeks

Exclusion Criteria:

  • Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted
  • Active allergic bronchopulmonary aspergillosis
  • Active and actively treated non tuberculosis mycobacterial (NTM) infection or tuberculosis
  • Primary diagnosis of Chronic obstructive pulmonary disease (COPD)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Ciprofloxacin DPI 28 Days on/off (Cipro 28)
Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
Drug: Ciprofloxacin DPI (BAYQ3939)
Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
EXPERIMENTAL: Ciprofloxacin DPI 14 Days on/off (Cipro 14)
Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
Drug: Ciprofloxacin DPI (BAYQ3939)
Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
PLACEBO_COMPARATOR: Placebo 28 Days on/off (Placebo 28)
Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
Drug: Placebo
Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
PLACEBO_COMPARATOR: Placebo 14 Days on/off (Placebo 14)
Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
Drug: Placebo
Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Time to First Exacerbation Event Within 48 Weeks
Time Frame: Up to Week 48
Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms.
Up to Week 48

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks
Time Frame: Up to Week 48
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms over 48 weeks.
Up to Week 48
Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks
Time Frame: Up to Week 48
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and worsening of at least one sign/symptom over 48 weeks.
Up to Week 48
Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46)
Time Frame: End of treatment (Week 44/46)
Pathogen eradication was defined as a negative culture result for all pre-specified pathogens at end of treatment (week 44 or 46 depending on treatment regimen) that were present in the participant at baseline. There was no imputation for participants who discontinued the study prematurely.
End of treatment (Week 44/46)
Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46)
Time Frame: Baseline and end of treatment (Week 44/46)
The SGRQ was a validated, disease-specific instrument that measures health-related quality of life (HRQoL) in adults with chronic obstructive pulmonary disease (COPD) and asthma and was later validated for use in bronchiectasis. The SGRQ covers 3 dimensions: symptoms, activity and impact on daily life. To determine the outcome, a score ranging from 1 to 100 was calculated for each individual domain and for the total score, and smaller scores indicate better health status. For this outcome measure, the symptoms component score was reported.
Baseline and end of treatment (Week 44/46)
Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46)
Time Frame: End of treatment (Week 44/46)
New pathogens were any of the pre-specified organisms not cultured before start of study medication. There was no imputation for participants who discontinued the study prematurely.
End of treatment (Week 44/46)
Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46)
Time Frame: Baseline and end of treatment (Week 44/46)
The QoL-B was a disease-specific questionnaire developed for non-Cystic fibrosis Bronchiectasis. It covers 8 dimensions: physical functioning, role functioning, emotional functioning, social functioning, vitality, treatment burden, health perceptions, and respiratory symptoms. Each dimension was scored separately on a scale of 0 to 100, and higher scores represent better outcomes. For this outcome measure, the respiratory symptoms domain score was reported.
Baseline and end of treatment (Week 44/46)
Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46)
Time Frame: Baseline and end of treatment (Week 44/46)
FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS).
Baseline and end of treatment (Week 44/46)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bayer

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Novartis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 2, 2013

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 9, 2016

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 9, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 8, 2013

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 8, 2013

First Posted (ESTIMATE)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 10, 2013

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 24, 2018

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 3, 2018

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 15625
  • 2011-004208-39 (EUDRACT_NUMBER)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings